论文部分内容阅读
目的探讨前列地尔注射液联合厄贝沙坦治疗早期糖尿病肾病的临床效果。方法将血压正常的早期2型糖尿病肾病患者60例随机分为治疗组及对照组,各30例,治疗组患者给予前列地尔注射液联合厄贝沙坦治疗,对照组患者给予厄贝沙坦治疗,两组疗程均为6个月。观察治疗前后两组血糖、24 h尿白蛋白排泄率、血液流变学、肾功能的变化。结果治疗后治疗组患者24 h尿白蛋白排泄率明显低于对照组,治疗组血液流变学、肾功能的各项参数水平指标较对照组明显改善(P<0.01)。结论前列地尔注射液联合厄贝沙坦治疗早期糖尿病肾病疗效肯定。
Objective To investigate the clinical efficacy of alprostadil combined with irbesartan in the treatment of early diabetic nephropathy. Methods Sixty patients with early normotensive type 2 diabetic nephropathy were randomly divided into treatment group (n = 30) and control group (n = 30). The patients in the treatment group were treated with alprostadil and prostaglandin injection. The patients in the control group were given irbesartan Treatment, two courses of treatment are 6 months. Before and after treatment, the changes of blood glucose, urinary albumin excretion rate, hemorheology and renal function were observed. Results The urinary albumin excretion rate of patients in the treatment group was significantly lower than that of the control group 24 h after treatment. The indexes of hemorheology and renal function in the treatment group were significantly improved (P <0.01). Conclusion Alprostadil combined with irbesartan in the treatment of early diabetic nephropathy is effective.